FDA Grants Approval to Iovance Biotherapeutics’ Lifileucel as First One-Time Cell Therapy for Solid Tumor and TIL Therapy
FDA Approves Iovance Biotherapeutics’ Lifileucel, Revolutionary TIL Therapy for Melanoma Treatment Pictured: The Iovance Cell Therapy Center/courtesy of Iovance Biotherapeutics Friday, the FDA granted approval to Iovance Biotherapeutics’ lifileucel as the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy. Amtagvi, as lifileucel will be known commercially, was approved … Read more